Morning Brief — Wednesday, August 12, 2026

Market Overview

Futures are pointing modestly higher (+0.2% SPY) as July CPI came in line with expectations, removing the immediate threat of a surprise rate hike and giving bulls a clear lane. The AI infrastructure trade is dominating the tape — CoreWeave’s blowout Q2 (revenue +112%, backlog $104B) and Super Micro’s monster guidance ($72B FY2027 target) are pulling the entire AI ecosystem higher in sympathy. The 10-year yield hovers near 4.7%, a level that keeps growth names on a short leash, but the earnings momentum is strong enough to override rate anxiety for today.

Claude’s Call

UP — The combination of in-line CPI (rate hike fears shelved), a genuine AI earnings wave from CRWV/SMCI/NBIS, and strong consumer data from HRB and KTB gives bulls a credible multi-sector catalyst to work with. S&P 500 trends higher today, with tech and AI infrastructure leading; watch the 4.7% 10-year yield as the circuit breaker — if it spikes on the CPI print, the rally fades fast.

Top Movers

CRWV (+21.6%) — $109.85 → $119.77 (+9.0% upside from fib 23.6%) Thesis: This is the real deal — revenue doubled to $2.6B, backlog hit $104B, and management called it “an important inflection point.” CRWV is the purest AI cloud infrastructure play in the market right now, and the backlog number is genuinely jaw-dropping. The stock is currently sitting right at fib 38.2% retracement ($108.50) from the 6-month swing, which acts as both confirmation and a logical entry zone for anyone who missed the initial pop. The caveat: debt keeps climbing in lockstep with revenue, which is a structural risk in a rising-rate world. Levels: Exit at $119.77 (fib 23.6% resistance). Support at $108.50 (fib 38.2%) / $91.05 (50d SMA).

SMCI (+10.8%) — $35.00 → $38.85 (+11.0% upside) Thesis: Super Micro guided to $72B in FY2027 revenue — that’s not a typo. Revenue soared 93% and the company received over $60B in new orders. This is a margin recovery story layered on top of an AI demand story, which is a potent combo. Technically, SMCI is right at the fib 38.2% retracement from its 6-month high ($38.85), and the stock has been grinding through prior resistance at $35.35 (fib 50%). RSI at 63 is elevated but not overbought — there’s room to push. Dell and HPE are already rallying in sympathy, which validates the read-through thesis. Levels: Exit at $38.85 (fib 38.2% / near-term resistance). Support at $35.35 (fib 50%) / $31.15 (50d SMA).

ATRO (+17.0%) — $87.61 → $97.33 (+11.1% upside) Thesis: Astronics posted record Q2 sales of $260M (+27% YoY), expanded EBITDA margins to 19.8%, and raised full-year guidance through $1 billion — all genuine operational beats, not accounting tricks. This is a quality aerospace supplier firing on all cylinders as aviation demand remains structurally strong. The stock is trading right at its 6-month high ($87.15), which it’s now breaking through. RSI at 21.59 is a data anomaly worth flagging — it may reflect a calculation artifact given the sharp move, but the fundamental momentum here is unambiguous. Year-to-date return of 59% is impressive but the raised guidance gives it legs. Levels: Exit at $97.33 (fib 1.272 extension). Support at $78.32 (fib 23.6%) / $73.62 (50d SMA).

HRB (+17.2%) — $54.71 → $62.44 (+14.1% upside) Thesis: H&R Block’s strongest performance in five years — revenue +4.9%, adjusted EPS +13.9%, client conversion at a five-year high — and they guided FY2027 with confidence. This isn’t a sexy AI story, but it’s a real earnings beat with a credible catalyst. The stock is at a fresh 6-month high with the 50d SMA at $40.39 providing a very distant but strong floor. RSI at 32 looks anomalously low for a name making new highs — take it with a grain of salt, but the underlying business momentum justifies the move. Tax prep is a sticky, recurring business and this was a clean print. Levels: Exit at $62.44 (fib 1.272 extension). Support at $48.55 (fib 23.6%) / $44.56 (fib 38.2%).

SE (+14.6%) — $131.51 → $146.02 (+11.1% upside) Thesis: Sea Limited is at a fresh 6-month high after Shopee and Monee drove 48% revenue growth and management is targeting $1B adjusted EBITDA — that’s a material milestone for a company that burned cash aggressively for years. The stock’s 224% 3-year run looks stretched on multiples, but the EBITDA trajectory is finally validating the thesis for patient holders. Technically, SE is at the very top of its 6-month range and breaking out with RSI at 27 (again, likely a data artifact) — the real question is whether $131.51 becomes a support ceiling or a springboard. The fib 1.272 extension at $146.02 is a clean target. Levels: Exit at $146.02 (fib 1.272 extension). Support at $118.92 (fib 23.6%) / $101.01 (50d SMA).

DFTX (+11.2%) — $45.50 → $57.34 (+26.0% upside) Thesis: Definium Therapeutics just landed its second positive Phase 3 study in short order — DT120 for generalized anxiety disorder hit both primary and key secondary endpoints. Two clean Phase 3 wins for an LSD-based platform is genuinely newsworthy and de-risks the regulatory path substantially. Vol ratio at 0.93 is the highest near-normal reading in this list, suggesting actual institutional participation. This stock was previously described as heading for its worst day in 9 months going into the data — the relief rally here is real and momentum-backed. Levels: Exit at $57.34 (fib 1.272 extension). Support at $40.73 (fib 23.6%) / $38.67 (50d SMA).

ALMR (+30.7%) — $36.57 → $41.53 (+13.5% upside) Thesis: Alamar Biosciences printed 82% revenue growth with a record 60% gross margin and an expanded ADDI partnership — for a post-IPO biotech (April IPO), this is an exceptionally clean debut earnings report. The 147% consumables growth suggests the razor/blade model is working. However, the stock is at its 6-month high with vol ratio at only 0.05 — that’s a major red flag. Very thin volume on a 30%+ move suggests this is illiquid and fragile, not institutional conviction. Levels: Exit at $41.53 (fib 1.272 extension). Support at $32.57 (fib 23.6%) / $25.09 (50d SMA). Caution: extremely low volume — this can reverse violently.

KTB (+12.5%) — $84.35 → $95.48 (+13.2% upside) Thesis: Kontoor Brands (Wrangler, Lee jeans) beat earnings by 41.5% with revenue up 18.5% and announced an accelerated share buyback. The earnings beat is massive and the buyback is a direct catalyst for near-term price support. RSI at 4.88 is almost certainly a data error but the stock has been consolidating below $88 resistance — this beat could be the breakout catalyst. Full-year revenue guidance came in 0.6% below consensus, which is the minor knock. Sector sympathy risk is low — this is company-specific execution. Levels: Exit at $95.48 (fib 1.272 extension). Support at $81.83 (fib 23.6%) / $80.93 (50d SMA).

Headlines to Watch

“CoreWeave’s Revenue Doubled, but Its Debt Keeps Climbing” — The $104B backlog is extraordinary, but rising debt in a 4.7% rate environment is a structural overhang; watch whether management addresses leverage on follow-up analyst calls.
“Super Micro Stock Jumps After Earnings Beat — Revenue Soars 93%, $72B Guidance” — This is a live demand barometer for the entire AI server ecosystem; Dell and HPE are already rallying in sympathy, and the read-through to NVDA is directly positive.
“Definium Therapeutics Unveils Second Positive Phase 3 Study for LSD-Based Drug” — Two clean Phase 3 wins puts DFTX on the regulatory fast track; watch for NDA filing timeline commentary and whether a larger pharma starts circling.
“Riot Platforms Soars 17% on $9.1B Anthropic Data Center Deal” — Former Bitcoin miners pivoting to AI infrastructure are rapidly repricing; IREN is in this bucket and today’s move needs to be assessed against whether company-specific AI deals are imminent or this is pure sympathy.
“CPI Comes In-Line, Futures Gain Pre-Bell” — In-line inflation is the green light the market needed; a hotter-than-expected print would have torched today’s AI rally instantly, so the all-clear is a genuine positive for risk assets into Jackson Hole.
“SpaceX, in FCC Letter, Calls for Strict ‘Use It or Lose It’ Spectrum Rules” — This is a direct catalyst for NextNav (NN), which needs FCC approval for its 900 MHz network; SpaceX’s position effectively validates the spectrum scarcity argument NN has been making.
“Bloom Energy Stock Is Up 153% This Year — Can the Rally Continue?” — BE’s AI data center power thesis is intact (MiTAC deployment announced), but at 153% YTD and below the 50d SMA, today’s 16.7% move on no new mega-catalyst warrants skepticism.

Claude’s Top Picks

CRWV (+21.6% today, +22.2% week) — $109.85 → $119.77 (+9.0% upside) Valuation: EV/EBITDA of 27.2x vs. peer median of 18.9x looks elevated, but on 112% revenue growth with a $104B backlog, this is justified — you’re buying scarcity of AI cloud capacity, not a legacy multiple. Upside: The backlog-to-revenue conversion story is just beginning; $104B in contracted future revenue at current pace means multi-year hypergrowth is locked in, not speculative. Risk: Debt keeps climbing and any rate spike or customer concentration issue (Microsoft dependency) could reprice this violently — it’s a high-beta name, not a value anchor.

SMCI (+10.8% today, +15.4% week) — $35.00 → $38.85 (+11.0% upside) Valuation: No forward P/E comp available, but $72B FY2027 guidance at current market cap implies a very low forward revenue multiple — this is cheap relative to the growth rate being delivered. Upside: $60B+ in new orders is not a guidance sandbag — it’s purchase orders, and the margin recovery story (previously the stock’s Achilles heel) is finally materializing alongside revenue acceleration. Risk: SMCI has a history of governance and accounting issues that have burned holders before; any hint of audit complications or earnings restatement risk would wipe out this entire rally and then some.

ATRO (+17.0% today, +13.6% week) — $87.61 → $97.33 (+11.1% upside) Valuation: Forward P/E of 30x vs. peer median of 24.6x is “FAIR” per comps — modest premium for a company growing revenue 27% with expanding margins crossing $1B in annual revenue for the first time. Upside: The guidance raise to $1.02-$1.04B is a clean fundamental catalyst, and aerospace demand remains structurally strong with no signs of slowing — this isn’t a one-quarter wonder. Risk: Trading at its 6-month high with a 59% YTD return means there are a lot of winners looking to take profits; any macro aerospace scare (airline capex cuts) would accelerate the selloff from elevated levels.

DFTX (+11.2% today, +2.5% week) — $45.50 → $57.34 (+26.0% upside) Valuation: Clinical-stage biotech — valuation is binary on Phase 3 outcomes, and with two positive studies now in hand, the risk-adjusted value has improved dramatically. No peer P/E comp is meaningful here. Upside: Two back-to-back Phase 3 wins for a novel LSD-based platform is a genuine regulatory de-risking event; with vol ratio near 1.0 and the stock still well below its 6-month high of $48.45, there’s technical runway. Risk: FDA is notoriously unpredictable on psychedelic-adjacent therapies; any signal of an advisory committee rejection or label restriction could cut this in half from current levels.

KTB (+12.5% today, +0.8% week) — $84.35 → $95.48 (+13.2% upside) Valuation: No forward P/E comp in the dataset, but a 41.5% EPS beat with revenue +18.5% and an accelerated buyback makes the pre-announcement valuation look deeply discounted in retrospect. Upside: The buyback announced today is a direct floor mechanism — management is literally buying stock at these levels, which limits downside and creates mechanical support. Risk: Full-year revenue guidance was 0.6% below consensus, which is a minor miss that could weigh on near-term analyst upgrades; also, consumer discretionary faces headwinds from 4.7% rates pressuring discretionary spending.

Avoid

ALMR — Up 30% on thin volume (vol ratio: 0.05) at a fresh 6-month high with no institutional footprint visible; this is a post-IPO biotech with massive illiquidity risk — the same vacuum that sent it up 30% can suck it back down 30% with one sell order.

BE — Up 153% YTD on a day where the only catalyst is a MiTAC microgrid deployment and sympathy with AI power names; trading below its 50d SMA ($249.88), which means the recent trend is still down — this looks like a dead-cat bounce, not a resumption of the primary uptrend.

GERN — Up 10% on no new news today, continuing a multi-week momentum run; at $1.63 with RSI-based momentum unclear and a 51% three-year decline still on the books, this is speculative noise around RYTELO revenue guidance that was already released August 5th — the catalyst is stale and the price is floating on fumes.

WSB Sentiment Check

HTZ — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — HTZ is at $2.54, down 67% from its 6-month high of $7.81, still in bankruptcy-adjacent territory with every fib support level ($3.92 to $6.32) sitting far above current price; this is a distressed name with 720 WSB mentions and 1,736 upvotes, which historically marks a squeeze attempt on weak fundamentals — the setup looks like hopium, not a real recovery thesis.

NBIS — WSB says: BULLISH (80% bullish) Claude says: AGREE — Nebius delivered a genuine 454% revenue growth print in Q2, the AI cloud demand is real and structural, and the stock has 14.65% single-day reaction with analyst target at $250.75 vs. current $220; trading right at fib 38.2% support ($210.33), the technical setup backs the fundamental bull case here.

MU — WSB says: MIXED (55% bullish) Claude says: PARTIALLY — Micron is a legitimate AI memory beneficiary (HBM for Nvidia) but at $908.74 it’s well below its 6-month high of $1,213 and sitting between fib 38.2% ($872) and fib 23.6% ($1,003) support/resistance; the mixed WSB sentiment is appropriate — it’s not a broken story, but it’s not a clear catalyst moment either, and the 50d SMA at $965 is overhead resistance.

SMCI — WSB says: BULLISH (80% bullish) Claude says: AGREE — The $72B revenue target and $60B+ in orders is not retail hopium, it’s a real print with real institutional read-through; RSI at 63 is elevated but not extreme, and the stock is sitting right at fib 50% ($35.35), making this a technically sound level to be bullish from.

CRWV — WSB says: BULLISH (80% bullish) Claude says: AGREE — Rare case where WSB is riding a genuinely institutional-grade catalyst; $104B backlog, 112% revenue growth, and management calling an “inflection point” is not meme energy — it’s fundamental re-rating, and the technicals (sitting at fib 38.2% support of $108.50) confirm the entry zone is reasonable for new money.

Earnings Scorecard

CRWV — BEAT (Revenue +112%, backlog $104B) | Stock: +21.6% | Reported: Tuesday After Close Reaction justified — this wasn’t priced in; $104B backlog is a structural re-rating event, not a one-quarter beat, and the 21.6% move looks insufficient given the magnitude of the backlog revelation. Still a buy at the fib 38.2% level.

SMCI — BEAT (Revenue +93%, guided to $72B FY2027) | Stock: +10.8% | Reported: Tuesday After Close Reaction may be under-done — $72B guidance is an enormous number that suggests the market hasn’t fully digested it yet; watch for analyst target upgrades to push this higher intraday.

SE — BEAT (Revenue +48%, targeting $1B EBITDA) | Stock: +14.6% | Reported: Tuesday/Wednesday Reaction justified — the EBITDA target is the key milestone the market has been waiting for; Sea Limited proving it can monetize its e-commerce and fintech scale is a genuine narrative shift. Hold with $146 target.

NBIS — BEAT (Revenue +454%) | Stock: +14.65% | Reported: Tuesday After Close Reaction is probably under-done — 454% revenue growth in AI cloud with exponential demand commentary from the CEO; analyst target of $250.75 vs. $220 current suggests 14% additional upside is the base case. Buy-the-dip on any pullback.

HRB — BEAT (Revenue +4.9%, EPS +13.9%, 5-year best) | Stock: +17.2% | Reported: Wednesday Before Open Reaction justified — clean beat with confident FY2027 guidance; 17% is a big move for a tax prep company, but five-year highs on multiple metrics warrant the re-rating. Trim into $62 fib extension.

ATRO — BEAT (Revenue +27%, raised guidance to $1B+, record bookings) | Stock: +17.0% | Reported: Tuesday After Close Reaction justified — record revenue, record bookings, record backlog, margin expansion, and guidance raise above $1B threshold is a clean catalyst. Fib 1.272 at $97.33 is the target.

CAVA — BEAT (Same-store sales, traffic beat) | Stock: +15.9% | Reported: Tuesday After Close Reaction justified and arguably under-done — traffic growth is the metric Wall Street cares most about for restaurant concepts, and beating on both SSS and traffic simultaneously in a tough consumer environment is exceptional. Analyst target $90.38 vs. current price.

BETA — MISS (Wider-than-expected loss) | Stock: -7.55% | Reported: Tuesday Reaction justified — a wider-than-expected loss for a pre-revenue aerospace company is a cash burn signal that rightfully spooks investors; avoid until there’s a clear path to contract revenue.

COHR — BEAT (Benefiting from photonics/optical networking wave) | Stock: +7.28% | Reported: Wednesday Reaction may be insufficient — Lumentum’s blowout print lifted the entire optical networking space, and Coherent as the larger, more diversified player has more room to re-rate; analyst target at $394.62 is well above current levels.

JD — IN LINE/SLIGHT MISS | Stock: -2.0% | Reported: Tuesday Reaction arguably overdone — China internet names face structural discount, but JD.com with $1.37 EPS and analyst target of $39.75 vs. a stock trading near current levels suggests the sell was more macro China anxiety than fundamental disappointment. Speculative contrarian value.

CSCO — BEAT ($2.95 EPS) | Stock: +2.4% | Reported: Tuesday After Close Reaction is insufficient on paper but appropriate in context — Cisco is a mature business and $2.95 against estimates is solid execution, but the AI networking upside hasn’t fully materialized in revenue yet; hold, don’t chase.

QUBT — IN LINE (Revenue beat, EPS matched) | Stock: 0.0% | Reported: Tuesday Market is right to be nonplussed — quantum computing commercial scaling is still 12-18 months from meaningful revenue; the flat reaction on a revenue beat/EPS match is exactly correct. No edge here yet.